The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
Abstract
Nanoparticle formulations for packaging existing drugs have been used to treat cancer. Lipoplatin is a liposomal cisplatin encapsulated into liposome nanoparticles of an average diameter of 110 nm. Lipoplatin has substantially reduced the renal toxicity, peripheral neuropathy, ototoxicity, myelotoxicity as well as nausea/vomiting and asthenia of cisplatin in Phase I, II and III clinical studies with enhanced or similar efficacy to cisplatin. During clinical development, 10- to 200-fold higher accumulation of Lipoplatin in solid tumors compared to adjacent normal tissue was found in patients. Targeting of tumor vasculature by Lipoplatin in animals suggested its antiangiogenesis potential and Lipoplatin was proposed to act like a double-sword: as chemotherapy and an antiangiogenesis drug. Lipoplatin has finished successfully one Phase III non-inferiority clinical study as first-line against NSCLC in its combination with paclitaxel showing statistically significant reduction in nephrotoxicity; two more Phase III studies are in progress, one in NSCLC with gemcitabine also showing noninferiority with reduced toxicity and another in squamous cell carcinoma of the head and neck with 5-fluorouracil. A registrational Phase II/III study against pancreatic cancer is in progress under the orphan drug status granted to Lipoplatin by the European Medicines Agency. Phase II studies are continuing in advanced breast cancer with vinorelbine and gastrointestinal cancers with radiotherapy and 5-fluorouracil. The highlights of the clinical development of Lipoplatin are reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505
Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
Kang, M. H., & Reynolds, C. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0144 · Cited by 1,016
Koepsell, H., Lips, K., & Volk, C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9254-z · Cited by 988
Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
Stresemann, C., & Lyko, F. (2008) · International Journal of Cancer · doi:10.1002/ijc.23607 · Cited by 949
Three-Dimensional Structure of the Apoptosome
Acehan, D., Jiang, X., Morgan, D. G., Heuser, J. E., Wang, X., & Akey, C. W. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00442-2 · Cited by 911
Yuan, F., Leunig, M., Huang, S. K., Berk, D. A., Papahadjopoulos, D., & Jain, R. K. (1994) · PubMed · Cited by 908
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Rougier, P., Adenis, A., Ducreux, M., de Forni, M., Bonneterre, J., Dembak, M., Clouet, P., Lebecq, A., Baille, P., Lefresne-Soulas, F., et al. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00072-1 · Cited by 751
Safaei, R., Larson, B. J., Cheng, T. C., Gibson, M. A., Otani, S., Naerdemann, W., & Howell, S. B. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0102 · Cited by 564
Lasic, D. D., Martin, F. J., Gabizon, A., Huang, S. K., & Papahadjopoulos, D. (1991) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(91)90162-2 · Cited by 545
Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity
Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J. W., Chen, X., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0769 · Cited by 431
Cisplatin nephrotoxicity: molecular mechanisms.
Hanigan, M. H., & Devarajan, P. (2003) · PubMed · Cited by 390
Drummond, D. C., Noble, C. O., Guo, Z., Hong, K., Park, J. W., & Kirpotin, D. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4007 · Cited by 380
Yonezawa, A., Masuda, S., Yokoo, S., Katsura, T., & Inui, K.-I. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110346 · Cited by 344
Ali, B. H., & Al Moundhri, M. S. (2006) · Food and Chemical Toxicology · doi:10.1016/j.fct.2006.01.013 · Cited by 328
Sorenson, C. M., & Eastman, A. R. (1988) · PubMed · Cited by 306
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
Crinò, L., Scagliotti, G., Marangolo, M., Figoli, F., Clerici, M., De Marinis, F., Salvati, F., Cruciani, G., Dogliotti, L., Pucci, F., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.297 · Cited by 303
How to Stabilize Phospholipid Liposomes (Using Nanoparticles)
Zhang, L., & Granick, S. (2006) · Nano Letters · doi:10.1021/nl052455y · Cited by 278
Song, I.-S., Savaraj, N., Siddik, Z. H., Liu, P., Wei, Y., Wu, C. J., & Kuo, M. T. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1543.3.12 · Cited by 259
Yokoo, S., Yonezawa, A., Masuda, S., Fukatsu, A., Katsura, T., & Inui, K.-I. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.03.004 · Cited by 250
The pathological role of Bax in cisplatin nephrotoxicity
Wei, Q., Dong, G., Franklin, J., & Dong, Z. (2007) · Kidney International · doi:10.1038/sj.ki.5002256 · Cited by 228
Choo, A. Y., & Blenis, J. (2009) · Cell Cycle · doi:10.4161/cc.8.4.7659 · Cited by 210
Gridelli, C., Aapro, M., Ardizzoni, A., Balducci, L., De Marinis, F., Kelly, K., Le Chevalier, T., Manegold, C., Perrone, F., Rosell, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.224 · Cited by 196
Harrington, K. J., Lewanski, C. R., Northcote, A. D., Whittaker, J., Wellbank, H., Vile, R. G., Peters, A. M., & Stewart, J. S. W. (2001) · Annals of Oncology · doi:10.1023/a:1011199028318 · Cited by 182
White, S. C., Lorigan, P. C., Margison, G. P., Margison, J. M., Martin, F., Thatcher, N., Anderson, H., & Ranson, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603345 · Cited by 152
Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells
Zisowsky, J., Koegel, S., Leyers, S., Devarakonda, K. R., Kassack, M. U., Osmak, M., & Jaehde, U. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.10.003 · Cited by 150
A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer
Kim, E. S., Lu, C., Khuri, F. R., Tonda, M. E., Glisson, B. S., Liu, D., Jung, M., Hong, W. K., & Herbst, R. S. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00278-1 · Cited by 136
Vaccine Entrapment in Liposomes
Gregoriadis, G., McCormack, B., Obrenovic, M., Saffie, R., Zadi, B., & Perrie, Y. (1999) · Methods · doi:10.1006/meth.1999.0841 · Cited by 135
Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts
Boulikas, T. (2004) · Oncology Reports · doi:10.3892/or.12.1.3 · Cited by 134
Self-citationNehmé, A., Baskaran, R., Aebi, S. P., Fink, D. A., Nebel, S., Cenni, B., Wang, J. Y. J., Howell, S. B., & Christen, R. D. (1997) · PubMed · Cited by 129
Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): Phase I study
Stathopoulos, G. P., Boulikas, T., Vougiouka, M., Deliconstantinos, G., Rigatos, S., Darli, E., Viliotou, V., & Stathopoulos, J. (2005) · Oncology Reports · doi:10.3892/or.13.4.589 · Cited by 128
Self-citationSystemic Lipoplatin infusion results in preferential tumor uptake in human studies.
Boulikas, T., Stathopoulos, G. P., Volakakis, N., & Vougiouka, M. (2005) · PubMed · Cited by 126
Self-citationStathopoulos, G. P., Antoniou, D., Dimitroulis, J., Michalopoulou, P., Bastas, A., Marosis, K., Stathopoulos, J., Provata, A., Yiamboudakis, P., Veldekis, D., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq234 · Cited by 125
Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin
Terwogt, J. M. M., Groenewegen, G., Pluim, D., Maliepaard, M., Tibben, M. M., Huisman, A., Huinink, W. W. T. B., Schot, M. E., Welbank, H., Voest, E. E., et al. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100371 · Cited by 124
Huang, S. K., Martin, F. J., Jay, G. D., Vogel, J. C., Papahadjopoulos, D., & Friend, D. S. (1993) · PubMed · Cited by 123
Hitzman, C. J., Elmquist, W. F., Wattenberg, L. W., & Wiedmann, T. S. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20591 · Cited by 119
Humes, H. D. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb00278.x · Cited by 116
Histone deacetylase inhibitors: Apoptotic effects and clinical implications (Review)
Emanuele (1992) · International Journal of Oncology · doi:10.3892/ijo_00000049 · Cited by 100
Mylonakis, N., Athanasiou, A. E., Ziras, N., Angel, J., Rapti, A., Lampaki, S., Politis, N., Karanikas, C. A., & Kosmas, C. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.06.017 · Cited by 98
Role of glutathione S -transferase P1-1 in the cellular detoxification of cisplatin
Peklak-Scott, C., Smitherman, P. K., Townsend, A. J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0250 · Cited by 98
Yokoo, S., Masuda, S., Yonezawa, A., Terada, T., Katsura, T., & Inui, K. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023168 · Cited by 98
Low renal toxicity of lipoplatin compared to cisplatin in animals.
Devarajan, P., Tarabishi, R., Mishra, J., Ma, Q., Kourvetaris, A., Vougiouka, M., & Boulikas, T. (2004) · PubMed · Cited by 91
Self-citationTaxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review
Rigas, J. R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_2-16 · Cited by 79
Stathopoulos, G., Boulikas, T., Vougiouka, M., et al. (2006) · Oncology Reports · doi:10.3892/or.15.5.1201 · Cited by 75
Self-citationVeal, G. J., Griffin, M. J., Price, E., Parry, A., Dick, G., Little, M., Yule, S. M., Morland, B. J., Estlin, E., Hale, J., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1723 · Cited by 69
Plasencia, C., Martinez‐Balibrea, E., Martínez‐Cardús, A., Quinn, D. I., Abad, A., & Neamati, N. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.1.225 · Cited by 69
Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines
Kitada, N., Takara, K., Minegaki, T., Itoh, C., Tsujimoto, M., Sakaeda, T., & Yokoyama, T. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0640-3 · Cited by 67
Ginsberg, M. S., Grewal, R. K., & Heelan, R. T. (2007) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2006.10.004 · Cited by 66
Owatari, S., Akune, S., Komatsu, M., Ikeda, R., Firth, S. D., Che, X., Yamamoto, M., Tsujikawa, K., Kitazono, M., Ishizawa, T., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3096 · Cited by 63
Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer
Liang, S., Lin, T., Ding, J., Pan, Y., Dang, D., Guo, C., Zhi, M., Zhao, P., Sun, L. J., Hong, L., et al. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0064-2 · Cited by 58
Rosenthal, D. I., Yom, S. S., Liu, L., et al. (2002) · Investigational New Drugs · doi:10.1023/a:1016201732368 · Cited by 51
Koukourakis, M. I., Giatromanolaki, A. N., Pitiakoudis, M., Kouklakis, G., Tsoutsou, P. P., Abatzoglou, I. M., Panteliadou, M., Sismanidou, K., Sivridis, E., & Boulikas, T. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.07.1733 · Cited by 50
Self-citationJehn, C., Boulikas, T., Kourvetaris, A., Possinger, K., & Lüftner, D. (2007) · PubMed · Cited by 46
Self-citationVillar, J., Quadri, H. S., Song, I., Tomita, Y. A., Tirado, Ò. M., & Notario, V. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2922 · Cited by 43
Platinum transporters and drug resistance
Choi, M., & Kim, D. (2006) · Archives of Pharmacal Research · doi:10.1007/bf02969293 · Cited by 42
Cancer gene therapy with targeted adenoviruses
Bachtarzi, H., Stevenson, M., & Fisher, K. D. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425240802507636 · Cited by 42
Al-Janadi, A., Chandana, S. R., & Conley, B. A. (2008) · Drugs in R&D · doi:10.2165/0126839-200809060-00003 · Cited by 38
Ravaioli, A., Papi, M., Pasquini, E., Marangolo, M., Rudnas, B., Fantini, M., Nicoletti, S., Drudi, F., Panzini, I., Tamburini, E., et al. (2009) · Journal of Chemotherapy · doi:10.1179/joc.2009.21.1.86 · Cited by 34
Jehn, C., Boulikas, T., Kourvetaris, A., Kofla, G., Possinger, K., & Lüftner, D. (2008) · PubMed · Cited by 31
Self-citationActivity of lipoplatin in tumor and in normal cells in vitro
Arienti, C., Tesei, A., Ravaioli, A., Ratta, M., Carloni, S., Mangianti, S., Ulivi, P., Nicoletti, S., Amadori, D., & Zoli, W. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283114fb2 · Cited by 25
Gao, G., Jingwei, J., Liang, X., Zhou, X., Huang, R., Chu, Z., & Zhan, Q. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2008.11.019 · Cited by 25
Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs
Marr, A. K., Kurzman, I. D., & Vail, D. M. (2004) · American Journal of Veterinary Research · doi:10.2460/ajvr.2004.65.1474 · Cited by 24
Froudarakis, Μ. E., Pataka, A., Pappas, P., Anevlavis, S., Argiana, E., Nikolaidou, M., Kouliatis, G., Pozova, S., Μαρσέλος, Μ., & Bouros, D. E. (2008) · Cancer · doi:10.1002/cncr.23921 · Cited by 24
MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal
Fedier, A., Poyet, C., Perucchini, D., Boulikas, T., & Fink, D. A. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200603000-00010 · Cited by 23
Self-citationBcl-2 cleavages at two adjacent sites by different caspases promote cisplatin-induced apoptosis
Zhu, J., Ying, Y., & Wu, J. (2007) · Cell Research · doi:10.1038/cr.2007.36 · Cited by 21
Present treatment and future expectations in advanced pancreatic cancer.
Stathopoulos, G. P., Androulakis, N., Souglakos, J., Stathopoulos, J., & Georgoulias, V. (2008) · PubMed · Cited by 20
An update of new targets for cancer treatment: vessels and matrix
Bicknell, R. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf634 · Cited by 17
Villedieu, M., Briand, M., Duval, M., Héron, J., Gauduchon, P., & Poulain, L. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.12.019 · Cited by 16
Vokes, E. E., Gordon, G. S., Mauer, A. M., Rudin, C. M., Krauss, S. A., Szeto, L. L., Golomb, H. M., & Hoffman, P. C. (2000) · Clinical Lung Cancer · doi:10.3816/clc.2000.n.025 · Cited by 15
Farhat, F., Kattan, J., Ibrahim, K., Bitar, N., Haddad, N., Tamraz, S., Hatoum, H. A., & Shamseddine, A. I. (2010) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(10)70478-x · Cited by 14
Li, Y., Gui-sheng, Q., Gui-jun, H., Chen, F., Qian, P., Yu, S., Wang, C., Li, Q., Wang, J., & Wu, G. (2006) · PubMed · Cited by 14
Karpathiou, G., Argiana, E., Koutsopoulos, A. V., & Froudarakis, Μ. E. (2007) · Oncology · doi:10.1159/000136800 · Cited by 13
DNA methylation: A promising target for the twenty-first century
Abreu, P. A., Dellamora-Ortiz, G. M., Leão-Ferreira, L. R., Gouveia, M., Braggio, E., Zalcberg, I. R., Santos, D. O., Bourguinhon, S., Cabral, L. M., Rodrigues, C. R., et al. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.8.1035 · Cited by 13
Cross-resistance of platinum derivatives in H-1R, a cisplatin-resistant cell line
Tanzawa (1994) · Oncology Reports · doi:10.3892/or_00000243 · Cited by 11
Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin
Wang, R., Zhang, X., Wang, G., Chen, X.-C., Tian, L., Yang, H.-S., Hu, M., Peng, F., Yang, J.-L., He, Q.-M., et al. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700958 · Cited by 8
Fedier, A., Erdmann, R., Boulikas, T., & Fink, D. A. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.5.1303 · Cited by 5
Self-citation
Cited by
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Exosomes in tumor microenvironment influence cancer progression and metastasis
Kahlert, C., & Kalluri, R. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1020-6 · Cited by 872
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
The role of exosomes in cancer metastasis
Steinbichler, T. B., Dudás, J., Riechelmann, H., & Skvortsova, I.-I. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.006 · Cited by 389
Metadata
- Authors
- Boulikas, T.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2009-07-15
- Volume
- 18
- Issue
- 8
- Pages
- 1197-1218
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W1963654724
- Cited by
- 276
- References
- 80
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.